NASDAQ:EVAX Evaxion Biotech A/S Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. $2.24 +0.01 (+0.45%) (As of 07/6/2022 12:10 PM ET) Add Compare Share Today's Range$2.24▼$2.3050-Day Range$1.60▼$3.0452-Week Range$1.51▼$25.04Volume275 shsAverage Volume34,444 shsMarket Capitalization$51.97 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Evaxion Biotech A/S MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside837.5% Upside$21.00 Price TargetShort InterestHealthy0.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.27) to ($1.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.60 out of 5 starsMedical Sector923rd out of 1,426 stocksBiological Products, Except Diagnostic Industry155th out of 218 stocks 3.5 Analyst's Opinion Consensus RatingEvaxion Biotech A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, Evaxion Biotech A/S has a forecasted upside of 837.5% from its current price of $2.24.Amount of Analyst CoverageEvaxion Biotech A/S has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.77% of the outstanding shares of Evaxion Biotech A/S have been sold short.Short Interest Ratio / Days to CoverEvaxion Biotech A/S has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion Biotech A/S has recently increased by 2.99%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEvaxion Biotech A/S does not currently pay a dividend.Dividend GrowthEvaxion Biotech A/S does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVAX. Previous Next 2.7 News and Social Media Coverage News SentimentEvaxion Biotech A/S has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Evaxion Biotech A/S this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 4.65% of the stock of Evaxion Biotech A/S is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Evaxion Biotech A/S are expected to decrease in the coming year, from ($1.27) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evaxion Biotech A/S is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evaxion Biotech A/S is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvaxion Biotech A/S has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address About Evaxion Biotech A/S (NASDAQ:EVAX) StockEvaxion Biotech A/S, an artificial intelligence (AI)-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in Phase 2b trial for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are in pre-clinical stage for the treatment of infectious diseases. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate; and a clinical trial collaboration and supply agreement with MSD International GmbH and MSD International Business GmbH. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hørsholm, Denmark.Read More EVAX Stock News HeadlinesJune 30, 2022 | finance.yahoo.comEvaxion Biotech Announces Gonorrhea as Second Bacterial Product TargetJune 23, 2022 | finance.yahoo.comEvaxion Biotech To Test EVX-03 DNA Vaccine For Non-Small Cell Lung CancerJuly 6, 2022 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! June 23, 2022 | finance.yahoo.comEvaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung CancerJune 7, 2022 | finance.yahoo.comEvaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park CapitalMay 20, 2022 | seekingalpha.comEvaxion Biotech files offering to sell up to $100M ordinary sharesMay 11, 2022 | seekingalpha.comEvaxion Biotech A/S' (EVAX) CEO Lars Wegner on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | investing.comEvaxion Biotech Tops Q1 EPS by 8cJuly 6, 2022 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! May 11, 2022 | benzinga.comEvaxion Biotech: Q1 Earnings InsightsMay 11, 2022 | finance.yahoo.comEvaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business UpdateMay 10, 2022 | seekingalpha.comDanish biotech, Evaxion surges after production update on personalized cancer candidateMay 10, 2022 | finance.yahoo.comEvaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02April 28, 2022 | benzinga.comEvaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage MelanomaApril 6, 2022 | finance.yahoo.comEvaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer ImmunotherapiesMarch 22, 2022 | finance.yahoo.comEvaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateMarch 14, 2022 | seekingalpha.comEvaxion Biotech appoints Karmark as CFO, Nissen as COOMarch 14, 2022 | finance.yahoo.comEvaxion Biotech Strengthens Management Team with Two Senior AppointmentsJanuary 26, 2022 | finance.yahoo.comEvaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with MerckJanuary 25, 2022 | finance.yahoo.comEvaxion Biotech AS Sponsored ADR (EVAX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?January 18, 2022 | finance.yahoo.comEvaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of MelanomaDecember 29, 2021 | finance.yahoo.comDo Options Traders Know Something About Evaxion (EVAX) Stock We Don't?November 9, 2021 | finance.yahoo.comEvaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNovember 9, 2021 | finance.yahoo.comEvaxion Biotech Announces Q3 2021 Financial Results and Provides Business UpdateNovember 5, 2021 | finanznachrichten.deEvaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA (pembrolizumab) in Patients with MelanomaNovember 5, 2021 | finance.yahoo.comEvaxion Biotech Announces Pricing of $24.0 Million Follow-on Public OfferingNovember 4, 2021 | marketwatch.comEvaxion Biotech Shares Double in Heavier-Than-Normal TradeSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVAX CUSIPN/A CIK1828253 Webwww.evaxion-biotech.com Phone45-5353-1850FaxN/AEmployees61Year FoundedN/ACompany Calendar Last Earnings5/11/2022Today7/06/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$21.00 High Stock Price Forecast$21.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+837.5%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,530,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.83% Return on Assets-78.88% Debt Debt-to-Equity Ratio0.37 Current Ratio7.55 Quick Ratio7.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book1.57Miscellaneous Outstanding Shares23,200,000Free FloatN/AMarket Cap$51.97 million OptionableNot Optionable Beta-0.13 Evaxion Biotech A/S Frequently Asked Questions Should I buy or sell Evaxion Biotech A/S stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Evaxion Biotech A/S stock. View analyst ratings for Evaxion Biotech A/S or view top-rated stocks. What is Evaxion Biotech A/S's stock price forecast for 2022? 1 analysts have issued twelve-month price objectives for Evaxion Biotech A/S's stock. Their EVAX stock forecasts range from $21.00 to $21.00. On average, they expect Evaxion Biotech A/S's stock price to reach $21.00 in the next year. This suggests a possible upside of 837.5% from the stock's current price. View analysts' price targets for Evaxion Biotech A/S or view top-rated stocks among Wall Street analysts. How has Evaxion Biotech A/S's stock performed in 2022? Evaxion Biotech A/S's stock was trading at $4.42 at the beginning of 2022. Since then, EVAX shares have decreased by 49.3% and is now trading at $2.24. View the best growth stocks for 2022 here. When is Evaxion Biotech A/S's next earnings date? Evaxion Biotech A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Evaxion Biotech A/S. How were Evaxion Biotech A/S's earnings last quarter? Evaxion Biotech A/S (NASDAQ:EVAX) posted its quarterly earnings results on Wednesday, May, 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.10. During the same quarter last year, the company earned ($0.23) EPS. View Evaxion Biotech A/S's earnings history. Who are Evaxion Biotech A/S's key executives? Evaxion Biotech A/S's management team includes the following people: Dr. Lars Aage-Staal Wegner M.D., Chief Exec. Officer (Age 47, Pay $610k)Dr. Niels Iversen Moeller M.D., Co-Founder, VP of Bus. & Director (Age 43, Pay $268k)Mr. Andreas Holm Mattsson, Co-Founder & Chief Innovation Officer (Age 46, Pay $290k)Dr. Birgitte Rono Ph.D., Chief Scientific Officer (Age 46, Pay $309k)Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D., Chief Medical Officer (Age 54, Pay $532k)Mr. Bo Lokke Karmark, Chief Financial Officer (Age 57)Mr. Jesper Nyegaard Nissen, COO & Interim CFO (Age 52)Dr. Jürgen Langhärig EMBA, Ph.D., Head of Bus. Devel. & Member of Advisory Board Who are some of Evaxion Biotech A/S's key competitors? Some companies that are related to Evaxion Biotech A/S include VectivBio (VECT), Gritstone bio (GRTS), CEL-SCI (CVM), CEL-SCI (CVM), Dynamics Special Purpose (DYNS), Graphite Bio (GRPH), INmune Bio (INMB), Poseida Therapeutics (PSTX), Ikena Oncology (IKNA), Jounce Therapeutics (JNCE), Genfit (GNFT), Fennec Pharmaceuticals (FENC), Taysha Gene Therapies (TSHA), ARYA Sciences Acquisition Corp IV (ARYD) and BioAtla (BCAB). View all of EVAX's competitors. When did Evaxion Biotech A/S IPO? (EVAX) raised $31 million in an IPO on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager. What is Evaxion Biotech A/S's stock symbol? Evaxion Biotech A/S trades on the NASDAQ under the ticker symbol "EVAX." How do I buy shares of Evaxion Biotech A/S? Shares of EVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Evaxion Biotech A/S's stock price today? One share of EVAX stock can currently be purchased for approximately $2.24. How much money does Evaxion Biotech A/S make? Evaxion Biotech A/S (NASDAQ:EVAX) has a market capitalization of $51.97 million. The company earns $-24,530,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. How many employees does Evaxion Biotech A/S have? Evaxion Biotech A/S employs 61 workers across the globe. How can I contact Evaxion Biotech A/S? Evaxion Biotech A/S's mailing address is BREDGADE 34E, COPENHAGEN K G7, 1260. The official website for Evaxion Biotech A/S is www.evaxion-biotech.com. The company can be reached via phone at 45-5353-1850 or via email at info@evaxion-biotech.com. This page (NASDAQ:EVAX) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
